Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1995 Mar;71(3):438–441. doi: 10.1038/bjc.1995.89

Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer.

I Ito 1, M Yoshimoto 1, T Iwase 1, S Watanabe 1, T Katagiri 1, Y Harada 1, F Kasumi 1, S Yasuda 1, T Mitomi 1, M Emi 1, et al.
PMCID: PMC2033649  PMID: 7880720

Abstract

To investigate possible relationships between genetic alterations and hormonal deregulation during breast cancer development and/or progression, we examined 616 primary breast cancers for loss of heterozygosity (LOH) at chromosomal regions 16q24, 17p13.3 and 17q21, and for amplifications of the ERBB2 and c-MYC loci. A comparison of oestrogen receptor (ER) and progesterone receptor (PgR) status in tumour cells with data concerning these genetic alterations revealed that LOH at 17q21 was significantly correlated with absence of oestrogen receptors (ER) (P < 0.0003) or progesterone receptors (PgR) (P < 0.0001), and with the absence of both (P < 0.0001). Similarly, a significant association was observed between amplification of ERBB2 and the absence of either ER or PgR. LOH at 17p13.3 was associated with the absence of PgR (P < 0.01). These data suggest a possible relationship between specific genetic changes on chromosome 17 and hormonal deregulation in the progression of breast cancer.

Full text

PDF
438

Images in this article

439Figure 1
on p.439

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berns E. M., Klijn J. G., van Staveren I. L., Portengen H., Noordegraaf E., Foekens J. A. Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: correlation with steroid receptors. Eur J Cancer. 1992;28(2-3):697–700. doi: 10.1016/s0959-8049(05)80129-7. [DOI] [PubMed] [Google Scholar]
  2. Borg A., Baldetorp B., Fernö M., Killander D., Olsson H., Sigurdsson H. ERBB2 amplification in breast cancer with a high rate of proliferation. Oncogene. 1991 Jan;6(1):137–143. [PubMed] [Google Scholar]
  3. Bragg T., Nakamura Y., Gill J., O'Connell P., Leppert M., Lathrop G. M., Lalouel J. M., White R. Isolation and mapping of a polymorphic DNA sequence pTBAB5.7 on chromosome 2 (D2S47). Nucleic Acids Res. 1987 Dec 10;15(23):10072–10072. doi: 10.1093/nar/15.23.10072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bufton L., Mohandas T. K., Magenis R. E., Sheehy R., Bestwick R. K., Litt M. A highly polymorphic locus on chromosome 16q revealed by a probe from a chromosome-specific cosmid library. Hum Genet. 1986 Dec;74(4):425–431. doi: 10.1007/BF00280499. [DOI] [PubMed] [Google Scholar]
  5. Callahan R., Campbell G. Mutations in human breast cancer: an overview. J Natl Cancer Inst. 1989 Dec 6;81(23):1780–1786. doi: 10.1093/jnci/81.23.1780. [DOI] [PubMed] [Google Scholar]
  6. Cornelis R. S., Devilee P., van Vliet M., Kuipers-Dijkshoorn N., Kersenmaeker A., Bardoel A., Khan P. M., Cornelisse C. J. Allele loss patterns on chromosome 17q in 109 breast carcinomas indicate at least two distinct target regions. Oncogene. 1993 Mar;8(3):781–785. [PubMed] [Google Scholar]
  7. Emi M., Takahashi E., Koyama K., Okui K., Oshimura M., Nakamura Y. Isolation and mapping of 88 new RFLP markers on human chromosome 8. Genomics. 1992 Aug;13(4):1261–1266. doi: 10.1016/0888-7543(92)90044-s. [DOI] [PubMed] [Google Scholar]
  8. Feinberg A. P., Vogelstein B. "A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity". Addendum. Anal Biochem. 1984 Feb;137(1):266–267. doi: 10.1016/0003-2697(84)90381-6. [DOI] [PubMed] [Google Scholar]
  9. Fujiwara Y., Monden M., Mori T., Nakamura Y., Emi M. Frequent multiplication of the long arm of chromosome 8 in hepatocellular carcinoma. Cancer Res. 1993 Feb 15;53(4):857–860. [PubMed] [Google Scholar]
  10. Henderson B. E., Ross R., Bernstein L. Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res. 1988 Jan 15;48(2):246–253. [PubMed] [Google Scholar]
  11. Horwitz K. B. Mechanisms of hormone resistance in breast cancer. Breast Cancer Res Treat. 1993;26(2):119–130. doi: 10.1007/BF00689685. [DOI] [PubMed] [Google Scholar]
  12. Inazawa J., Saito H., Ariyama T., Abe T., Nakamura Y. High-resolution cytogenetic mapping of 342 new cosmid markers including 43 RFLP markers on human chromosome 17 by fluorescence in situ hybridization. Genomics. 1993 Jul;17(1):153–162. doi: 10.1006/geno.1993.1297. [DOI] [PubMed] [Google Scholar]
  13. Kondoleon S., Vissing H., Luo X. Y., Magenis R. E., Kellogg J., Litt M. A hypervariable RFLP on chromosome 17p13 is defined by an arbitrary single copy probe p144-D6 [HGM9 No. D17S34]. Nucleic Acids Res. 1987 Dec 23;15(24):10605–10605. doi: 10.1093/nar/15.24.10605. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Martin M. B., Saceda M., Lindsey R. K. Regulatory mechanisms in breast cancer. Estrogen and progesterone receptors. Cancer Treat Res. 1991;53:273–288. [PubMed] [Google Scholar]
  15. Nakamura Y., Fujimoto E., O'Connell P., Leppert M., Lathrop G. M., Lalouel J. M., White R. Isolation and mapping of a polymorphic DNA sequence (pEFD64.2) on chromosome 3 [D3S46]. Nucleic Acids Res. 1988 Oct 11;16(19):9354–9354. doi: 10.1093/nar/16.19.9354. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Nakamura Y., Leppert M., O'Connell P., Wolff R., Holm T., Culver M., Martin C., Fujimoto E., Hoff M., Kumlin E. Variable number of tandem repeat (VNTR) markers for human gene mapping. Science. 1987 Mar 27;235(4796):1616–1622. doi: 10.1126/science.3029872. [DOI] [PubMed] [Google Scholar]
  17. Sato T., Akiyama F., Sakamoto G., Kasumi F., Nakamura Y. Accumulation of genetic alterations and progression of primary breast cancer. Cancer Res. 1991 Nov 1;51(21):5794–5799. [PubMed] [Google Scholar]
  18. Sato T., Tanigami A., Yamakawa K., Akiyama F., Kasumi F., Sakamoto G., Nakamura Y. Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res. 1990 Nov 15;50(22):7184–7189. [PubMed] [Google Scholar]
  19. Slamon D. J., Clark G. M., Wong S. G., Levin W. J., Ullrich A., McGuire W. L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9;235(4785):177–182. doi: 10.1126/science.3798106. [DOI] [PubMed] [Google Scholar]
  20. Thompson A. M., Steel C. M., Chetty U., Hawkins R. A., Miller W. R., Carter D. C., Forrest A. P., Evans H. J. p53 gene mRNA expression and chromosome 17p allele loss in breast cancer. Br J Cancer. 1990 Jan;61(1):74–78. doi: 10.1038/bjc.1990.17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Yamamoto T., Ikawa S., Akiyama T., Semba K., Nomura N., Miyajima N., Saito T., Toyoshima K. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986 Jan 16;319(6050):230–234. doi: 10.1038/319230a0. [DOI] [PubMed] [Google Scholar]
  22. Yamashita H., Kobayashi S., Iwase H., Itoh Y., Kuzushima T., Iwata H., Itoh K., Naito A., Yamashita T., Masaoka A. Analysis of oncogenes and tumor suppressor genes in human breast cancer. Jpn J Cancer Res. 1993 Aug;84(8):871–878. doi: 10.1111/j.1349-7006.1993.tb02060.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES